Forest Labs will continue Alzheimer's studies

Forest Laboratories says that a new clinical trial of its experimental Alzheimer's drug showed sufficient clinical activity to warrant continued studies. About a year ago researchers at Forest reported that neramexane had failed a late-stage trial. The most recent study included 198 patients in 47 sites. Forest had hoped to include 400 subjects. In one set of comparisons, patients taking neramexane showed significant improvement after 12 weeks of treatment but not after 24 weeks.

- read this report from TheStreet.com for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.